Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies

Eur Respir J. 2021 Apr 1;57(4):2004315. doi: 10.1183/13993003.04315-2020. Print 2021 Apr.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Animals
  • Antitubercular Agents
  • Fluoroquinolones / adverse effects
  • Humans
  • Mice
  • Mycobacterium tuberculosis*
  • Ofloxacin

Substances

  • Antitubercular Agents
  • Fluoroquinolones
  • Ofloxacin